Nomura Strategic Ventures makes an investment in Nada
02/24/2025, Dallas, TX // KISS PR Brand Story PressWire //
Nada, a leading fintech platform pioneering home equity investment products for homeowners and investors, today announced that Nomura Strategic Ventures, LLC (NSV) has provided financing through its venture debt fund, NSV Fund 1, to support Nada's continued growth and innovation. The investment will accelerate Nada's expansion as an institutional-grade home equity agreement (HEA) originator and fuel the development of Homeshares, its investment platform providing individuals access to the home equity asset class.
This transaction provides Nada with flexible, non-dilutive capital and strengthens its engagement with Nomura to explore additional partnerships regarding HEA financing and capital markets strategies.
'We invest capital and also support the business-development objectives of startups,' said Neeraj Hora, CEO of NSV. 'We look forward to collaborating with Nada to explore future partnership opportunities around their home equity agreement asset.'
'In 2024, we experienced significant growth in our partner network and among homeowners embracing this exciting new asset class—home equity agreements. With the added support and partnership from Nomura, we are well-positioned to further accelerate our expansion.' said Tore Steen, CEO of Nada.
Nada is the first SEC-qualified issuer, providing individual investors access to the emerging home equity agreement (HEA) asset class. Through its Homeshares platform, Nada has introduced multiple investment products centered on HEAs, including the newly launched U.S. Home Equity Fund I, which offers investors a diversified portfolio of HEAs across the U.S. with an institutional-grade securitization exit strategy.
With its in-house originations team, Nada has enabled homeowners across 14 states to unlock home equity without taking on debt. As its capital stack expands, Nada has scaled HEA origination volume to over $10M per month and is well-positioned for continued growth as a market leader in the HEA space.
Nada is a fintech platform that offers innovative home equity investment solutions, allowing homeowners to access their home equity without taking on debt. Through its Homeshares investment platform, Nada provides investors with access to diversified residential real estate markets through fractional investments in home equity, supported by institutional-grade financial structures.
Nomura is a global financial services group with an integrated network spanning over 30 countries. By connecting markets East & West, Nomura services the needs of individuals, institutions, corporates and governments through its three business divisions: Retail, Wholesale (Global Markets and Investment Banking), and Investment Management. Founded in 1925, the firm is built on a tradition of disciplined entrepreneurship, serving clients with creative solutions and considered thought leadership. For further information about Nomura, visit www.nomura.com
About NSV
NSV is a subsidiary of Nomura Holding America Inc. and manages Nomura Strategic Ventures Fund 1 (NSV Fund 1) as well as the investment activities of the Nomura Group's Financial Innovation office in the United States.
This press release may contain forward-looking statements describing future expectations, plans, results, or strategies. These statements are subject to risks and uncertainties that may cause actual outcomes to differ materially from those projected. Changes in product offerings, regulatory plans, and business strategies are potential factors influencing such differences.
Media Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Nomura upbeat on Dr. Reddy's long-term prospects; maintains ‘Buy' call with Rs 1,575 target
By Markets Desk Published on June 12, 2025, 07:38 IST Nomura has maintained its Buy rating on Dr. Reddy's Laboratories, setting a target price of ₹1,575, following the company's strategic roadmap shared during a recent management interaction. The company laid out four key levers to sustain growth and profitability beyond the gRevlimid opportunity, including: Sustained growth in the base business, Significant upside potential from semaglutide, the blockbuster diabetes and weight-loss drug, Capacity to undertake selective acquisitions in the $2–2.5 billion range, and A strong focus on cost rationalisation, with plans to reduce operating expenses by 500 basis points — from 37% to 32% of sales — thereby maintaining EBITDA margins around 25%. Dr. Reddy's, a major Indian pharmaceutical company with a strong global presence, has expanded its footprint across generics, biosimilars, and active pharmaceutical ingredients (APIs). It has also been building its presence in high-value markets like the US, Europe, and emerging markets through a mix of organic growth and strategic deals. Nomura believes the combination of margin optimisation, pipeline monetisation (including complex generics like semaglutide), and balance sheet flexibility places the company in a strong position for long-term value creation. Disclaimer: The views and target prices mentioned are as stated by Nomura and do not represent the opinions or recommendations of this publication. Investors are advised to consult their financial advisors before making any investment decisions. Markets Desk at
Yahoo
4 hours ago
- Yahoo
Insmed Announces Pricing of $750 Million Public Offering of Common Stock
BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $96.00 per share. The gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately $750 million. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock. Insmed intends to use the net proceeds from this offering to fund continued research and development of brensocatib as well as pre-commercial and, if approved, commercialization activities related to brensocatib, activities related to the further commercialization and development of ARIKAYCE® (amikacin liposome inhalation suspension), further research and development of treprostinil palmitil inhalation powder (TPIP), INS1201, and the Company's pre-clinical research product candidates, and for other general corporate purposes, including business expansion activities. Goldman Sachs & Co. LLC, Leerink Partners, BofA Securities, Jefferies and J.P. Morgan are acting as joint book-running managers for the offering. Stifel is acting as co-lead manager for the offering. The offering is expected to close on June 13, 2025, subject to the satisfaction of customary closing conditions. The public offering of common stock described above is being made pursuant to Insmed's shelf registration statement on Form S-3 (File No. 333-272088) that was previously filed with the Securities and Exchange Commission (SEC) and became automatically effective on May 19, 2023. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Insmed Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Forward-looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements. The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timings discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the public offering; failure to continue to successfully commercialize ARIKAYCE, our only approved product, in the United States ("U.S."), Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain U.S., European or Japanese approval for ARIKAYCE; our inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that we will not successfully or in a timely manner complete the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE, or our failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to obtain, or delays in obtaining, regulatory approvals for brensocatib, TPIP or our other product candidates in the U.S., Europe or Japan or for ARIKAYCE outside the U.S., Europe or Japan, including separate regulatory approval for the Lamira® Nebulizer System in each market and for each usage; failure to successfully commercialize brensocatib, TPIP or our other product candidates, if approved by applicable regulatory authorities, or to maintain applicable regulatory approvals for brensocatib, TPIP or our other product candidates, if approved; uncertainties or changes in the degree of market acceptance of ARIKAYCE or, if approved, brensocatib, TPIP, or our other product candidates, by physicians, patients, third-party payors and others in the healthcare community; our inability to obtain and maintain adequate reimbursement from government or third-party payors for ARIKAYCE or, if approved, brensocatib, TPIP, or our other product candidates, or acceptable prices for ARIKAYCE or, if approved, brensocatib, TPIP, or our other product candidates; inaccuracies in our estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP, or our other product candidates or in data we have used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; failure of third parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE, brensocatib, or TPIP for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's business; the risks and uncertainties associated with, and the perceived benefits of, our senior secured loan with certain funds managed by Pharmakon Advisors, LP and our royalty financing with OrbiMed Royalty & Credit Opportunities IV, LP, including our ability to maintain compliance with the covenants in the agreements for the senior secured loan and royalty financing and the impact of the restrictions on our operations under these agreements; our inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of our product candidates that are approved in the future; failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP, or our other product candidates and our potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval of our product candidates or to permit the use of ARIKAYCE in the broader population of patients with Mycobacterium avium complex lung disease, among other things; development of unexpected safety or efficacy concerns related to ARIKAYCE, brensocatib, TPIP, or our other product candidates; risks that our clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected; failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products; the risk that the full data set from the TPIP study in pulmonary arterial hypertension ("PAH") or data generated in further clinical trials of TPIP will not be consistent with the topline results of the TPIP PAH study; risk that interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available or may be interpreted differently if additional data are disclosed, or that blinded data will not be predictive of unblinded data; risk that our competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product we are developing for a particular indication; our inability to attract and retain key personnel or to effectively manage our growth; our inability to successfully integrate our acquisitions and appropriately manage the amount of management's time and attention devoted to integration activities; risks that our acquired technologies, products and product candidates will not be commercially successful; inability to adapt to our highly competitive and changing environment; inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology; risk that we are unable to maintain our significant customers; risk that government healthcare reform materially increases our costs and damages our financial condition; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; risk that our current and potential future use of artificial intelligence and machine learning may not be successful; deterioration in general economic conditions in the U.S., Europe, Japan and globally, including the effect of prolonged periods of inflation, affecting us, our suppliers, third-party service providers and potential partners; the risk that we could become involved in costly intellectual property disputes, be unable to adequately protect our intellectual property rights or prevent disclosure of our trade secrets and other proprietary information, and incur costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on us by agreements related to ARIKAYCE, brensocatib or our other product candidates, including our license agreements with PARI Pharma GmbH and AstraZeneca AB, and failure to comply with our obligations under such agreements; the cost and potential reputational damage resulting from litigation to which we are or may become a party, including product liability claims; risk that our operations are subject to a material disruption in the event of a cybersecurity attack or issue; our limited experience operating internationally; changes in laws and regulations applicable to our business, including any pricing reform and laws that impact our ability to utilize certain third parties in the research, development or manufacture of our product candidates, and failure to comply with such laws and regulations; our history of operating losses, and the possibility that we never achieve or maintain profitability; goodwill impairment charges affecting our results of operations and financial condition; inability to repay our existing indebtedness and uncertainties with respect to our ability to access future capital; and delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans. The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Company filings with the SEC. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Contact: Investors: Bryan DunnVice President, Investor Relations(646) Media: Claire MulhearnVice President, Corporate Communications(862) 842-6819media@ View original content to download multimedia: SOURCE Insmed Incorporated Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
Coinbase claims to reduce account freezes by 82%
Coinbase claims to reduce account freezes by 82% originally appeared on TheStreet. Coinbase (Nasdaq: COIN), the largest crypto exchange in the U.S., has successfully reduced account freezes by 82%, CEO Brian Armstrong claimed on X on 6 June. Armstrong acknowledged that account freezes have been a major problem at the exchange for a long time, but the team has succeeded in largely fixing the issue. With account freezing reduced by 82%, more improvements to the system are anticipated, which the community will be kept updated on, Armstrong said. He urged users whose accounts are still restricted, except those sanctioned for illegal activity, to contact the support team to get the issue resolved quickly. Armstrong, in particular, hailed the efforts of Dor Levi for resolving the issue. Levi, who recently joined Coinbase's product team, credited the firm making significant investments in machine learning models, infrastructure, modeling, and teams for fewer account freezes. He added: The goal is clear: Account freezes should be rare, limited to situations that warrant them, primarily when we're legally obligated (e.g. sanctions or court orders) or protecting users (e.g. from scams or account compromises). Armstrong's post invited users complaining about customer service, account verification, and multiple account restrictions to which the CEO offered help. However, crypto influencer Wendy O decried: Damage is kinda done with retail Wendy added that most of her audience consists of retail users and they refuse to engage with Coinbase due to this issue that she claims has been going on since 2021. Though the company last month became the first crypto company to join the much-coveted S&P 500 list, Coinbase has been facing several challenges of late, such as a data leak affecting 69,461 users and the SEC investigating it for reportedly overstating user numbers. Coinbase claims to reduce account freezes by 82% first appeared on TheStreet on Jun 11, 2025 This story was originally reported by TheStreet on Jun 11, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
